The use of synthesised peptides & proteins is attractive in various areas of application like
Established production methods for peptides & proteins are prohibitively expensive at the required purity levels due to a lack of scalability.
Recently, cultured meat companies are struggling to find possibilities to scale production because of this issue as well
mk2 Biotechnologies developed a proprietary process that allows the scalable and cost-efficient production of high-purity peptides and proteins for mass market applications.
This innovative and scalable process eliminates the current bottlenecks of established synthesis methods and allows customers’ quality requirements to be fully met, while reducing production costs by several orders of magnitude. This means that bioactive peptides and proteins can be used for the first time in volume markets such as pharmaceuticals, cosmetics, food & beverages and agriculture.
In one of its flagship projects, mk2 Biotechnologies is aiming to lower cost in the lab-grown meat industry to enable price parity between cultured and naturally produced meat.
mk2 Biotechnologies is able to flexibly and effciently produce petides and proteins to target the known challenges of today, and the unknown ones of tomorrow.
Global market potential of € 100 billion for target peptides over all fields of application – animal health, agriculture, food & beverages, pharmaceuticals and cosmetics.
The three entry markets have potentials of € 43 billion (Growth Factors in cultured meat), € 70 billion (Monoclonal Antibody (mAb) Fragments in pharmaceuticals), and € 8bn (Aquaculture parasites) respectively.
Average growth rates (CAGRs) over all these markets lie above 10%.
Managing Director
Managing Director
CTO
Matthias Hofreiter
Bleiben Sie über die neusten Trends und Updates der Industrie mit unserem monatlichen Newsletter informiert.
© 2024 G8Way GmbH, Wien & München
